I'm LongbridgeAI, I can summarize articles.Shao-Lee Lin, CEO of Cue Biopharma, disclosed a 6.2% beneficial stake in the company via an SEC filing dated August 21, 2026. The disclosure details equity grants tied to her appointment and performance-based awards. While she may adjust her holdings based on market conditions, a trust blocker limits additional exercises to prevent ownership exceeding 4.99%. This reflects leadership-aligned ownership with potential for increased stakes as awards vest.
Shao-Lee Lin, President and CEO of Cue Biopharma, Inc., disclosed a 6.2% beneficial stake in the company’s common stock. The filing dated Aug. 21, 2026 details equity grants tied to her appointment and additional awards made in July, including performance-based units. The position reflects leadership-aligned ownership with options and RSUs that could increase her holdings as they vest or are exercised.
Investor Intent
Lin says she may buy more shares, sell some, or take other actions depending on her ongoing review of Cue Biopharma’s performance and market conditions. As CEO and a director, she “regularly explores potential actions and transactions that may be advantageous to the Issuer,” including mergers, acquisitions, reorganizations, or changes to governance or capital structure.
A blocker limits additional exercises by her trust: the purchased pre‑funded warrants and warrants cannot be exercised if doing so “would own more than 4.99%” of Cue Biopharma’s outstanding shares. Lin may also receive future equity awards for her executive service, which could raise her beneficial ownership over time.
Investor's Background
Shao-Lee Lin is a U.S. physician-executive who serves as President, Chief Executive Officer, and a director of Cue Biopharma, Inc. She brings senior leadership experience from large pharma and biotech roles, focusing on immunology and drug development. Lin typically aligns compensation with performance through stock, options, and milestone-based awards to support long-term value creation.
Original SEC Filing: Cue Biopharma, Inc. [ CUE ] - SCHEDULE 13D - Aug. 21, 2026